brenetafusp + kinase inhibitors

Combination therapy of **brenetafusp** (also known as IMC-F106C), an ImmTAC bispecific biologic targeting the cancer-testis antigen PRAME (preferentially expressed antigen in melanoma), administered together with one or more **kinase inhibitors**. Brenetafusp utilizes a soluble, affinity-enhanced T-cell receptor (TCR) fused to an anti-CD3 effector domain to redirect and activate T cells specifically toward PRAME-positive tumor cells. Multiple ongoing and completed clinical studies have evaluated brenetafusp both as monotherapy and in combination with other agents, including **kinase inhibitors** (the specific kinase inhibitors may be histology-dependent, such as BRAF or MEK inhibitors, or other targeted oral therapies). The primary indication is in advanced solid tumors, particularly metastatic or unresectable PRAME-positive cancers, including cutaneous melanoma and ovarian cancer. The combination aims to exploit complementary mechanisms—tumor-directed T cell engagement from brenetafusp alongside direct oncogenic pathway inhibition by kinase inhibitors[2][3][4][5][7].